Knee Implants Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Kneecap Replacement, Partial Knee Replacement, Total Knee replacement, Others), By Material (Cobalt-Chromium Alloys, Titanium Alloys, Stainless Steel, Ceramics, Polyethylene, Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers (ASCs), and Region Forecast 2020-2031

Knee Implants Market size was valued at US$ 11.1 billion in 2024 and is expected to reach US$ 15.7 billion by 2031, growing at a significant CAGR of 5.0% from 2025-2031. Knee implants are used in knee replacement surgery or arthroplasty to replace the damaged cartilage and bone to recreate the joint surface. Knee implants are made up of metal alloys, strong plastic parts, or ceramic materials. Knee implants are used in the kneecap replacement, complex knee replacement, partial knee replacement, and total knee replacement surgeries. Knee implantation is commonly performed for patients with rheumatoid arthritis, osteoarthritis, and psoriatic arthritis. Knee Implants is one of the most effective and widely used ways to relieve the knee arthritis pain.

Technological advancements in the market such as minimal invasive surgery, improved implant materials and their success rates are allowing even the younger population to undergo knee implants surgery ultimately driving the market significantly. The global market is also promoted by the technologies such as 3D printed knee implants which is being manufactured by the U.S. based medical company ConforMIS. Introduction of advanced technologies and products for are anticipated to keep the industry rivalry and market growth at par over the forecast period. For example, X3 Advanced Bearing Technology and Mako Robotic-Arm Assisted Technology with capabilities of providing patient-specific 3-D model to plan partial knee replacement surgery. As per the U.S. Department of Health & Human Services, it is estimated that around 294,000 children below the age of 18 suffer from arthritis or rheumatic condition in the U.S.

Key Developments:

• In November 2024, Zimmer Biomet Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Premarket Approval Application (PMA) Supplement approval for the Oxford® Cementless Partial Knee. The approval was based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing, supporting its use in cementless partial knee replacement (PKR).
• In September 2024, Maxx Orthopedics, Inc. received U.S. FDA clearance for the Freedom® Titan PCK Revision Knee System. Additionally, the company announced a strategic partnership with Unik Orthopedics (UNIKO), Inc., a firm specializing in personalized medical devices, robotics, and medical software for joint replacement procedures.
• In June 2024, Johnson & Johnson MedTech announced that DePuy Synthes received 510(k) FDA clearance for the VELYS™ Robotic-Assisted Solution in Unicompartmental Knee Arthroplasty (UKA). This expansion builds on the platform’s existing use in Total Knee Arthroplasty (TKA), which has been cleared in 20 markets and used in over 55,000 procedures. The system provides surgeons with critical data to help preserve soft tissue, predict joint stability, and enhance knee function restoration.